Annual CFO
-$32.38 M
-$7.15 M-28.37%
31 December 2023
Summary:
Cellectar Biosciences annual cash flow from operations is currently -$32.38 million, with the most recent change of -$7.15 million (-28.37%) on 31 December 2023. During the last 3 years, it has fallen by -$18.44 million (-132.38%). CLRB annual CFO is now -1249.55% below its all-time high of -$2.40 million, reached on 31 December 2005.CLRB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$9.17 M
+$4.97 M+35.18%
30 September 2024
Summary:
Cellectar Biosciences quarterly cash flow from operations is currently -$9.17 million, with the most recent change of +$4.97 million (+35.18%) on 30 September 2024. Over the past year, it has dropped by -$1.10 million (-13.62%). CLRB quarterly CFO is now -1469.42% below its all-time high of $669.40 thousand, reached on 30 June 2010.CLRB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$46.27 M
-$1.10 M-2.43%
30 September 2024
Summary:
Cellectar Biosciences TTM cash flow from operations is currently -$46.27 million, with the most recent change of -$1.10 million (-2.43%) on 30 September 2024. Over the past year, it has dropped by -$16.07 million (-53.23%). CLRB TTM CFO is now -15641.82% below its all-time high of -$293.90 thousand, reached on 31 March 2005.CLRB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLRB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.4% | -13.6% | -53.2% |
| 3 y3 years | -132.4% | -42.6% | -111.0% |
| 5 y5 years | -183.0% | -158.6% | -293.5% |
CLRB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -132.4% | at low | -103.2% | +35.2% | -112.8% | at low |
| 5 y | 5 years | -183.0% | at low | -241.9% | +35.2% | -295.6% | at low |
| alltime | all time | -1249.5% | at low | -1469.4% | +35.2% | <-9999.0% | at low |
Cellectar Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.17 M(-35.2%) | -$46.27 M(+2.4%) |
| June 2024 | - | -$14.14 M(+5.8%) | -$45.17 M(+17.1%) |
| Mar 2024 | - | -$13.36 M(+39.2%) | -$38.55 M(+19.1%) |
| Dec 2023 | -$32.38 M(+28.4%) | -$9.60 M(+18.9%) | -$32.38 M(+7.2%) |
| Sept 2023 | - | -$8.07 M(+7.1%) | -$30.19 M(+3.6%) |
| June 2023 | - | -$7.53 M(+4.8%) | -$29.14 M(+6.5%) |
| Mar 2023 | - | -$7.18 M(-3.1%) | -$27.37 M(+8.5%) |
| Dec 2022 | -$25.22 M(+11.8%) | -$7.41 M(+5.7%) | -$25.22 M(+13.0%) |
| Sept 2022 | - | -$7.01 M(+21.8%) | -$22.32 M(+2.7%) |
| June 2022 | - | -$5.76 M(+14.2%) | -$21.74 M(-4.9%) |
| Mar 2022 | - | -$5.04 M(+11.7%) | -$22.86 M(+1.3%) |
| Dec 2021 | -$22.57 M(+62.0%) | -$4.51 M(-29.8%) | -$22.57 M(+2.9%) |
| Sept 2021 | - | -$6.43 M(-6.5%) | -$21.93 M(+15.4%) |
| June 2021 | - | -$6.88 M(+44.7%) | -$19.00 M(+25.2%) |
| Mar 2021 | - | -$4.75 M(+22.8%) | -$15.17 M(+8.9%) |
| Dec 2020 | -$13.93 M(+19.1%) | -$3.87 M(+10.5%) | -$13.93 M(+9.3%) |
| Sept 2020 | - | -$3.50 M(+14.8%) | -$12.75 M(-0.3%) |
| June 2020 | - | -$3.05 M(-13.2%) | -$12.79 M(+3.2%) |
| Mar 2020 | - | -$3.51 M(+31.0%) | -$12.39 M(+6.0%) |
| Dec 2019 | -$11.69 M(+2.2%) | -$2.68 M(-24.4%) | -$11.69 M(-0.5%) |
| Sept 2019 | - | -$3.54 M(+33.6%) | -$11.76 M(+5.1%) |
| June 2019 | - | -$2.65 M(-5.8%) | -$11.18 M(+1.0%) |
| Mar 2019 | - | -$2.82 M(+2.6%) | -$11.07 M(-3.2%) |
| Dec 2018 | -$11.44 M(+3.8%) | -$2.74 M(-7.6%) | -$11.44 M(-0.7%) |
| Sept 2018 | - | -$2.97 M(+16.6%) | -$11.52 M(+3.8%) |
| June 2018 | - | -$2.55 M(-20.1%) | -$11.10 M(-1.1%) |
| Mar 2018 | - | -$3.18 M(+12.7%) | -$11.22 M(+1.8%) |
| Dec 2017 | -$11.02 M(+33.1%) | -$2.83 M(+11.1%) | -$11.02 M(+4.5%) |
| Sept 2017 | - | -$2.54 M(-4.5%) | -$10.54 M(+3.2%) |
| June 2017 | - | -$2.66 M(-10.8%) | -$10.21 M(+8.1%) |
| Mar 2017 | - | -$2.99 M(+27.2%) | -$9.45 M(+14.1%) |
| Dec 2016 | -$8.28 M(+0.8%) | -$2.35 M(+6.1%) | -$8.28 M(+11.5%) |
| Sept 2016 | - | -$2.21 M(+16.4%) | -$7.43 M(+0.7%) |
| June 2016 | - | -$1.90 M(+4.6%) | -$7.38 M(-3.7%) |
| Mar 2016 | - | -$1.82 M(+21.7%) | -$7.66 M(-6.7%) |
| Dec 2015 | -$8.21 M(-7.1%) | -$1.49 M(-31.0%) | -$8.21 M(-7.3%) |
| Sept 2015 | - | -$2.17 M(-1.0%) | -$8.86 M(+0.8%) |
| June 2015 | - | -$2.19 M(-7.6%) | -$8.79 M(+2.1%) |
| Mar 2015 | - | -$2.37 M(+10.5%) | -$8.61 M(-2.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | -$8.84 M(-3.4%) | -$2.14 M(+2.1%) | -$8.84 M(-5.7%) |
| Sept 2014 | - | -$2.10 M(+4.4%) | -$9.38 M(-4.6%) |
| June 2014 | - | -$2.01 M(-22.6%) | -$9.83 M(-0.3%) |
| Mar 2014 | - | -$2.59 M(-3.1%) | -$9.86 M(+7.7%) |
| Dec 2013 | -$9.15 M(+39.0%) | -$2.68 M(+4.9%) | -$9.15 M(+12.1%) |
| Sept 2013 | - | -$2.55 M(+25.6%) | -$8.17 M(+11.8%) |
| June 2013 | - | -$2.03 M(+7.7%) | -$7.31 M(+7.9%) |
| Mar 2013 | - | -$1.89 M(+11.5%) | -$6.77 M(+2.8%) |
| Dec 2012 | -$6.58 M(+10.3%) | -$1.69 M(+0.2%) | -$6.59 M(+2.5%) |
| Sept 2012 | - | -$1.69 M(+12.9%) | -$6.43 M(+2.5%) |
| June 2012 | - | -$1.50 M(-12.0%) | -$6.27 M(-14.7%) |
| Mar 2012 | - | -$1.70 M(+10.9%) | -$7.35 M(+23.1%) |
| Dec 2011 | -$5.97 M(+76.5%) | -$1.54 M(+0.3%) | -$5.97 M(+31.3%) |
| Sept 2011 | - | -$1.53 M(-40.6%) | -$4.55 M(+24.9%) |
| June 2011 | - | -$2.58 M(+694.4%) | -$3.64 M(+829.0%) |
| Mar 2011 | - | -$324.60 K(+187.0%) | -$391.80 K(-88.4%) |
| Dec 2010 | -$3.38 M(-68.1%) | -$113.10 K(-81.9%) | -$3.38 M(-39.1%) |
| Sept 2010 | - | -$623.50 K(-193.1%) | -$5.56 M(-24.0%) |
| June 2010 | - | $669.40 K(-120.2%) | -$7.31 M(-30.0%) |
| Mar 2010 | - | -$3.32 M(+44.9%) | -$10.44 M(-1.7%) |
| Dec 2009 | -$10.62 M(-38.7%) | -$2.29 M(-3.7%) | -$10.62 M(-5.7%) |
| Sept 2009 | - | -$2.38 M(-3.6%) | -$11.26 M(-14.6%) |
| June 2009 | - | -$2.46 M(-29.5%) | -$13.18 M(-20.0%) |
| Mar 2009 | - | -$3.49 M(+19.4%) | -$16.47 M(-5.0%) |
| Dec 2008 | -$17.33 M(+28.7%) | -$2.93 M(-31.9%) | -$17.33 M(-8.0%) |
| Sept 2008 | - | -$4.29 M(-25.4%) | -$18.83 M(+0.3%) |
| June 2008 | - | -$5.76 M(+32.1%) | -$18.78 M(+19.6%) |
| Mar 2008 | - | -$4.36 M(-1.6%) | -$15.71 M(+16.6%) |
| Dec 2007 | -$13.47 M(+108.2%) | -$4.43 M(+4.4%) | -$13.47 M(+19.1%) |
| Sept 2007 | - | -$4.24 M(+57.9%) | -$11.31 M(+20.5%) |
| June 2007 | - | -$2.68 M(+26.6%) | -$9.38 M(+19.7%) |
| Mar 2007 | - | -$2.12 M(-6.3%) | -$7.84 M(+21.2%) |
| Dec 2006 | -$6.47 M(+169.7%) | -$2.26 M(-2.1%) | -$6.47 M(+34.2%) |
| Sept 2006 | - | -$2.31 M(+102.5%) | -$4.82 M(+43.8%) |
| June 2006 | - | -$1.14 M(+52.1%) | -$3.35 M(+17.3%) |
| Mar 2006 | - | -$751.20 K(+22.2%) | -$2.86 M(+19.1%) |
| Dec 2005 | -$2.40 M | -$614.50 K(-27.1%) | -$2.40 M(+34.4%) |
| Sept 2005 | - | -$843.30 K(+30.3%) | -$1.78 M(+89.6%) |
| June 2005 | - | -$647.40 K(+120.3%) | -$941.30 K(+220.3%) |
| Mar 2005 | - | -$293.90 K | -$293.90 K |
FAQ
- What is Cellectar Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Cellectar Biosciences?
- What is Cellectar Biosciences annual CFO year-on-year change?
- What is Cellectar Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Cellectar Biosciences?
- What is Cellectar Biosciences quarterly CFO year-on-year change?
- What is Cellectar Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Cellectar Biosciences?
- What is Cellectar Biosciences TTM CFO year-on-year change?
What is Cellectar Biosciences annual cash flow from operations?
The current annual CFO of CLRB is -$32.38 M
What is the all time high annual CFO for Cellectar Biosciences?
Cellectar Biosciences all-time high annual cash flow from operations is -$2.40 M
What is Cellectar Biosciences annual CFO year-on-year change?
Over the past year, CLRB annual cash flow from operations has changed by -$7.15 M (-28.37%)
What is Cellectar Biosciences quarterly cash flow from operations?
The current quarterly CFO of CLRB is -$9.17 M
What is the all time high quarterly CFO for Cellectar Biosciences?
Cellectar Biosciences all-time high quarterly cash flow from operations is $669.40 K
What is Cellectar Biosciences quarterly CFO year-on-year change?
Over the past year, CLRB quarterly cash flow from operations has changed by -$1.10 M (-13.62%)
What is Cellectar Biosciences TTM cash flow from operations?
The current TTM CFO of CLRB is -$46.27 M
What is the all time high TTM CFO for Cellectar Biosciences?
Cellectar Biosciences all-time high TTM cash flow from operations is -$293.90 K
What is Cellectar Biosciences TTM CFO year-on-year change?
Over the past year, CLRB TTM cash flow from operations has changed by -$16.07 M (-53.23%)